Evercore ISI Remains a Buy on BioNTech SE (BNTX)
Evercore ISI analyst Cory Kasimov maintained a Buy rating on BioNTech SE today and set a price target of $130.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Kasimov covers the Healthcare sector, focusing on stocks such as Zenas BioPharma, Inc., Beam Therapeutics, and Vertex Pharmaceuticals. According to TipRanks, Kasimov has an average return of 16.8% and a 56.21% success rate on recommended stocks.
In addition to Evercore ISI, BioNTech SE also received a Buy from BMO Capital’s Evan Seigerman in a report issued today. However, on the same day, TD Cowen assigned a Hold rating to BioNTech SE (NASDAQ: BNTX).
Based on BioNTech SE’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.52 billion and a GAAP net loss of $28.7 million. In comparison, last year the company earned a revenue of $1.24 billion and had a net profit of $198.1 million
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BNTX in relation to earlier this year.
Read More on BNTX:
Disclaimer & DisclosureReport an Issue
- BioNTech price target lowered to $94 from $116 at TD Cowen
- BioNTech price target lowered to $125 from $134 at Morgan Stanley
- BioNTech price target lowered to $128 from $143 at BMO Capital
- BioNTech price target lowered to $130 from $145 at Citi
- Balancing Near-Term Headwinds and Strategic Transition: Why a Hold Rating Remains Warranted
